Credit rating agency, Brickwork Ratings has upgraded rating of Nectar Lifesciences’ long term bank facilities to ‘A’ from ‘A-’. The rating implies adequate degree of safety regarding timely servicing of financial obligation and such investment carry low credit risk.
The rating agency has also upgraded rating of the company’s short term bank facilities to ‘A2+’ from ‘A1’. The rating implies strong degree of safety regarding timely payment of financial obligation and such investment carry low credit risk.
Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.
